Nura Bio

Nura Bio Inc. is a biopharma company focused on discovering and developing neuroprotective drugs. It announced a publication on the structural and mechanistic regulation of SARM1.

Nura Bio announces over $140M in Series A financing, completion of Phase 1 study of NB-4746, and appointment of Shilpa Sambashivan, Ph.D. as CEO and Director.

Nura Bio raises $73.8M Series B to advance SARM1 inhibitors, dosing first ALS patient with NB-4746 and initiating first-in-human study of NB-9402.

Nura Bio announces the appointments of Lahar Mehta, M.D. as Chief Medical Officer, and Scott Greenberg as Chief Business Officer.

The company offers neuroprotective medicines aimed at overcoming debilitating neurological diseases.

Abe Bassan is a partner at Samsara and joined the firm in 2017, when the fund was launched.

Lahar is chief medical officer of Nura Bio, overseeing its clinical programs across neurological diseases. He previously led global clinical development and clinical pharmacology at Amylyx Pharmaceuticals, including work on amyotrophic lateral sclerosis (ALS).

Dr. Keswani is president and CEO of ImmunoBrain. He is a physician-scientist and former neurology faculty member at The Johns Hopkins Hospital, and held senior pharmaceutical industry positions, including at Roche.

Scott is Chief Business Officer of Nura Bio, overseeing business development. Scott previously served as Chief Operating Officer of Aro Biotherapeutics, leading fundraising, finance, business development, and corporate strategy.

Nura Bio was conceived in 2018 by The Column Group and its scientific founders to revolutionize the treatment of neurological diseases with novel, life-changing neuroprotective medicines.

A world where the diagnosis of a neurological disorder comes with the hope of a cure.

Nura Bio completes a $73.8 million Series B financing to advance clinical proof-of-biology studies for its SARM1 inhibitor assets, NB-4746 and NB-9402.

Jun 2026 · AllSciNews article

Nura Bio appoints Lahar Mehta, M.D., as chief medical officer and Scott Greenberg as chief business officer. The C-suite additions expand the company's leadership team, bringing in leadership intended to strengthen drug development and business strategy capabilities.

Feb 2025 · Nura BioNews article

Nura Bio adds $68 million to its Series A, bringing the financing beyond $140 million, and names cofounder Shilpa Sambashivan chief executive. Its lead drug, NB-4746, suppresses SARM1 to protect nerve axons and will progress into Phase 1b/2 studies.

Sep 2024 · BioPharma DiveNews article

Nura Bio initiates a Phase 1 clinical trial of NB-4746, its first-in-class oral, brain-penetrant SARM1 inhibitor. The randomized, double-blind, placebo-controlled study evaluates the candidate’s safety, tolerability, and pharmacokinetics in healthy volunteers.

Aug 2023 · Nura BioNews article